Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118199) titled 'A prospective cohort study of bevacizumab bio analogues combined with cindilimab and TACE in the treatment of unresectable HBV related liver cancer' on Feb. 3.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: West China Hospital, Sichuan University
Condition:
Hepatocellular carcinoma
Intervention:
TACE treatment after bevacizumab biological analog combined with cedilimumab:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-09
Target Sample Size: TACE treatment after bevacizumab biological analog combined with cedilimumab:75;TACE followed b...